The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy
David D‘Andrea(Medical University of Vienna), Marco Moschini(Vita-Salute San Raffaele University), Laura S. Mertens(Oncode Institute), Francesco Soria(Medical University of Vienna), Wojciech Krajewski(Wroclaw Medical University), Ettore De Berardinis(Policlinico Umberto I), Benjamin Pradère, Diego M. Carrión(Hospital Universitario de Torrejón), Fabrizio Di Maida(University of Florence), Martina Maggi(Policlinico Umberto I), Mario Álvarez‐Maestro(Hospital Universitario La Paz), David Paulnsteiner(Medical University of Vienna), Ekaterina Laukhtina(Sechenov University), Renate Pichler(Innsbruck Medical University), Kees Hendricksen(The Netherlands Cancer Institute), Shahrokh F. Shariat(Universitätszahnklinik Wien), Ettore Di Trapani(European Institute of Oncology), Stephan Brönimann(Medical University of Vienna), Sonia Vallet(Universitätsklinikum Krems), Andrea Mari(Azienda Ospedaliero-Universitaria Careggi), Francesco Del Giudice(Sapienza University of Rome), Guillaume Grisay, Bas W.G. van Rhijn(The Netherlands Cancer Institute), Ronan Filippot(Institut Gustave Roussy)
Cited by 14
Related Papers
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|793
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|618
Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)
|World Journal of Urology|2016|471
Urothelial Carcinoma of the Bladder and the Upper Tract: Disparate Twins
|The Journal of Urology|2012|359